FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. The use of a polypeptide specifically binding to oxidized phospholipid (OxPL) in the treatment of Kawasaki disease, where the polypeptide inhibits the biological activity of OxPL, is disclosed. In this case, the polypeptide contains: a variable heavy chain domain (VH) containing complementarity-determining regions (CDR) of the VH amino acid sequence represented in SEQ ID NO: 2, and a variable light chain domain (VL) containing the CDR of the VL amino acid sequence represented in SEQ ID NO: 2 or 4.
EFFECT: invention makes it possible to use it for the effective treatment of Kawasaki disease in a patient.
15 cl, 22 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
